SCHEMBL4334549

SCHEMBL4334549

Cc1ccc(-c2nc(C(=O)NC3(CO)CCOCC3)n3ccccc23)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 1/20 0.45
▸ EPAS1 Q99814 1/20 0.45
▸ MAP2K3 P46734 1/20 0.40
▸ HTR4 Q13639 6/20 0.39
▸ RORC P51449 4/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ DGAT2 Q96PD7 1/20 0.37
▸ RAD51 Q06609 1/20 0.36
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13578207 0.90 DGAT2 (0.46) MAP2K3HTR4RORCCNR2ALDH1A1
SCHEMBL4330621 0.90 RORC (0.42) MAP2K3HTR4RORCCNR2KDM4E
SCHEMBL4335846 0.90 HIF1A (0.46) HIF1AEPAS1MAP2K3HTR4RORC
SCHEMBL4328983 0.90 MAP3K14 (0.40) HIF1AEPAS1MAP2K3HTR4RORC
SCHEMBL4327073 0.89 MAP2K3 (0.54) HIF1AEPAS1MAP2K3HTR4RORC
SCHEMBL4327617 0.89 MAP2K3 (0.46) MAP2K3HTR4RORCCNR2DGAT2
SCHEMBL4332898 0.88 HIF1A (0.47) HIF1AEPAS1MAP2K3HTR4RORC
SCHEMBL4330451 0.88 HIF1A (0.46) HIF1AEPAS1MAP2K3HTR4RORC
SCHEMBL4324747 0.87 OPRD1 (0.41) MAP2K3HTR4RORCCNR2ALDH1A1
SCHEMBL4338454 0.86 DGAT2 (0.41) HIF1AEPAS1HTR4RORCCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 — — US disclosed
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 HIF1A 383/4885EPAS1 1743/4885MAP2K3 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback